NKTX - Nkarta, Inc.

2.77
-0.060   -2.166%

Share volume: 484,858
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$2.83
-0.06
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 23%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.14%
1 Month
38.50%
3 Months
13.99%
6 Months
32.54%
1 Year
42.05%
2 Year
-59.97%
Key data
Stock price
$2.77
P/E Ratio 
N/A
DAY RANGE
$2.75 - $2.90
EPS 
-$1.39
52 WEEK RANGE
$1.63 - $3.65
52 WEEK CHANGE
$30.66
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
71.290 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,240,731
AVERAGE 30 VOLUME 
$959,769
Company detail
CEO: Paul J. Hastings
Region: US
Website: nkartatx.com
Employees: 140
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.

Recent news